A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to FcƔRIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.

Trial Profile

A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to FcƔRIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs BI 1206 (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 23 Oct 2017 According to a BioInvent International media release, first data read-out is expected half of 2018.
    • 19 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 07 Jul 2016 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top